Professor and Chair, Department of Oncology
Member, Canadian Nuclear Safety CommissionOncologic ImagingDepartment of Oncology
University of Alberta
Cross Cancer Institute
11560 University Avenue
Edmonton, Alberta T6G 1Z2
— 131I mIBG and 111In Octreotide
— 131I ERC9
— Unsealed source therapy: mechanisms of effect
Novel radiopharmaceutical development
Molecular Imaging and Clinical Trial Design
— Imaging biomarkers
— Treatment stratification and treatment planning
— Assays of response
Dr. Alexander (Sandy) McEwan was appointed as member of the Canadian Nuclear Safety Commission on March 7, 2013.
Drever L, Robinson DM, McEwan AJB, Roa W. A Local Contrast Based Approach to Threshold Segmentation for PET Target Volume Delineation. Medical Physics 2006; 33(6):1583-1594.
Gulenchyn KY, McEwan AJ, Freeman M, Kiess M, O'Neill BJ, Beanlands RS, CANM, CSS. Treating the right patient at the right time: access to cardiovascular nuclear imaging. Can J Cardiol 2006; 22(1):827-833.
Alexander A, Murtha A, Abdulkarim B, Mehta V, Wheatley M, Murray B, Riauka T, Hanson J. Fulton D, McEwan A, Roa W. Prognostic significance of serial magnetic resonance spectroscopies over the course of radiation therapy for patients with malignant glioma. Clin Invest Med 2006; 29(5):301-311.
Sandler MP, McEwan AJ. Revoluntionizing the Future. RT Image 2006; 19(45). (www.rt-image.com.)
Murray D and McEwan AJ. Radiobiology of Systemic Radiation Therapy. Cancer Biotherapy and Radiopharmaceuticals 2007, 22(1):1-23.
Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, Benson A, Espat J, Bilbao JI, Sharma RA, Thomas JA, Coldwell D. Recommendations for Radioembolization of Hepatic Malignancies Using Yttrium-90 (Y90) Microsphere Brachytherapy: A Consensus Panel Report from the Radioembolization Brachytherapy Oncology Consortium (REBOC). Int J Rad Oncol Biol Phys 2007; 68(1):13-23.
Demeter S, Jacobs P, Chmielowiec C, Logus W, Hailey D, Fassbender K, McEwan AB. The Cost of Lung Cancer in Alberta. Can Resp J 2007; 14(2):81-86.
Joshua A, Sharma SK, Strelkov A, Scott JR, Martin-Iverson MT, Abrams DN, Silverstone PH, McEwan AJB. Synthesis and Biodistribution of 8-Iodo-11-(4-methylpiperazino)-5H-dibenzo[b,e][1,4]-diazepine: Iozapine. Bioorg Med Chem Lett 2007; 17: 4066-4069.
Drever L, Roa W, McEwan A, Robinson D. Comparison of three image segmentation techniques for target volume delineation in positron emission tomography. J Appl Clin Med Phys 2007; 8(2): 93-109.
Drever L, Roa W, McEwan A, Robinson D. Iterative threshold segmentation for PET target volume delineation. Med Phys 2007; 34(4): 1253-1265.
McEwan AJB. SNM Leadership Update: Molecular Imaging…Realistically…An Evolution in Nuclear Medicine Practice. J Nucl Med, 2007; 48(8): 31N, 38N.
McEwan AJB. How Do We Introduce the Next Generation of Radiotracers into Clinical Practice? SNM Leadership Update, J Nucl Med, 2007; 48(9): 28N, 30N.
Kumar P, Mercer, J, Doerksen C, Tonkin K, McEwan AJB. Clinical production, stability studies and PET imaging with 16--[18F]fluoroestradiol ([18F]FES) in ER positive breast cancer patients. J Pharm Pharmaceut Sci, 2007; 10(2); 256s-265s.
Emami S, Kumar P, Yang J, Kresolek Z, Paproski R, Cass C, McEwan AJB, Wiebe LI. Synthesis, transport and hypoxia-selective binding of 1--D-(5-deoxy-5-fluororibofuranosyl)-2-nitroimidazole (-5-FAZR), a configurational isomer of the clinical hypoxia marker, FAZA. J Pharm Pharmaceut Sci, 2007; 10(2): 237-245.
McEwan AJB. SNM Leadership Update: Funding Nuclear Medicine Research. J Nucl Med, 2007; 48(11); 23N.
McEwan AJB. Radiation Rules are Strict. Letter. USA Today, November 28, 2007.
McEwan AJB. SNM Leadership Update: Advocating for PET/CT. J Nucl Med, 2007; 48(12): 26N.